Bharat Biotech Revac-B+ hepatitis B vaccine crosses 150 M mark.

Bharat Biotech International Ltd (Bharat Biotech) has crossed production and delivery of more than 150 M doses of Revac-B+, recombinant hepatitis B vaccine since its launch in Oct 1998. Revac-B+ has been marketed and sold in more than 30 countries worldwide with manufacturing and quality standards on par with USFDA, EMEA and WHO guidelines. The Vaccine has established an excellent safety and efficacy profile since its launch in 1998. Bharat Biotech is a major supplier of the Cesium Chloride Free hepatitis-B Vaccines. It has taken steps to ensure a smooth transition for customers from the traditional hepatitis-B vaccine to the new preservative-free Revac-Bmcf (Thiomersol and …